DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6djlw2/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- AstraZeneca Plc
- BIOCAD
- Crinetics Pharmaceuticals, Inc.
- EffRx Pharmaceuticals S.A.
- Euroscreen S.A.
- Merck KGaA
- Vicore Pharma AB
Drug Profiles
- AZD-4901
- C-21
- choriogonadotropin alfa
- ESN-364
- follitropin alfa
- JDSCR-004
- KDT-501
- metformin hydrochloride
- Small Molecule to Antagonize FSH Receptor for Women's Health
- Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome
- Synthetic Peptide to Antagonize GPR54 for Women's Health, Male Health and Oncology
For more information visit http://www.researchandmarkets.com/research/6djlw2/polycystic
